Amer Karam Karam, MD
Gynecological Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Karam’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87777 · Current
Licensed to practise in California · since 2004 · expires 2028-05-31 · American University of Beirut Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$175,434
Medicare paid this office $175,434 for 352 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 138 | $25,029 | $104 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 24 | $19,460 | $811 |
| Long return visit (40+ min) | 40 | $10,457 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $8,265 | $71 |
| Return visit (30+ min) | 65 | $7,641 | $84 |
See all 14 services
| Return visit (30+ min) | 138 | $25,029 | $104 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 24 | $19,460 | $811 |
| Long return visit (40+ min) | 40 | $10,457 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $8,265 | $71 |
| Return visit (30+ min) | 65 | $7,641 | $84 |
| Short return visit (20+ min) | 81 | $5,660 | $62 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 20 | $4,669 | $233 |
| New patient visit (45+ min) | 35 | $4,361 | $125 |
| Imaging of lymph nodes during surgery | 23 | $3,637 | $158 |
| New patient visit (45+ min) | 28 | $2,945 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,851 | $150 |
| Long return visit (40+ min) | 13 | $2,616 | $131 |
| Short return visit (20+ min) | 39 | $2,143 | $52 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,866 | $117 |
Procedures Medicare counted
| Removal of the uterus | 33 | More than 97% of doctors who do this |
Who their Medicare patients are
352 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 8% · Also on Medicaid 26% · Health risk score 1.83. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 66% · Cancer 53% · Chronic kidney disease 20% · Depression 20% · Diabetes 19% · Coronary heart disease 19% · Heart failure 15% · Atrial fibrillation 13% · COPD 11% · Stroke 7% · Dementia 5%.
The office billed $1,171,367, Medicare allowed $223,875 and paid $175,434; for 1,015 services of 74 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 352 | 1,015 | 73 | 1.83 | $1,171,367 | $175,434 |
| 2023 | 319 | 974 | 73 | 1.65 | $895,671 | $147,954 |
| 2022 | 281 | 681 | 72 | 1.79 | $602,772 | $106,817 |
| 2021 | 330 | 986 | 72 | 1.91 | $1,069,197 | $173,744 |
| 2020 | 330 | 1,174 | 71 | 1.86 | $1,105,387 | $173,075 |
| 2019 | 306 | 911 | 71 | 2.00 | $826,698 | $156,242 |
| 2018 | 314 | 975 | 70 | 1.80 | $741,601 | $143,445 |
| 2017 | 235 | 795 | 70 | 1.93 | $731,379 | $124,526 |
| 2016 | 204 | 607 | 71 | 1.84 | $632,777 | $101,799 |
| 2015 | 176 | 608 | 70 | 1.67 | $789,223 | $125,348 |
| 2014 | 137 | 398 | 70 | 1.58 | $603,514 | $96,208 |
| 2013 | 161 | 306 | 69 | 1.72 | $246,592 | $51,102 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Return visit (30+ min) | 93 | $18,520 | $87 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 17 | $14,426 | $849 |
| Return visit (30+ min) | 81 | $13,152 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 34 | $7,223 | $73 |
| New patient visit (45+ min) | 43 | $5,122 | $119 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 17 | $4,294 | $253 |
| Short return visit (20+ min) | 63 | $4,054 | $51 |
| Short return visit (20+ min) | 65 | $3,716 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $3,228 | $120 |
| New patient visit (45+ min) | 27 | $3,191 | $118 |
| Imaging of lymph nodes during surgery | 17 | $2,910 | $171 |
| Long return visit (40+ min) | 14 | $2,527 | $133 |
| Long return visit (40+ min) | 12 | $1,729 | $133 |
2022: 10 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 15 | $12,770 | $851 |
| Return visit (30+ min) | 77 | $12,136 | $86 |
| Return visit (30+ min) | 72 | $11,931 | $86 |
| Short return visit (20+ min) | 50 | $3,302 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,243 | $66 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 13 | $3,154 | $243 |
| New patient visit (45+ min) | 24 | $2,867 | $119 |
| New patient visit (45+ min) | 26 | $2,733 | $105 |
| Short return visit (20+ min) | 45 | $2,641 | $49 |
| Imaging of lymph nodes during surgery | 12 | $1,861 | $155 |
2021: 17 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 32 | $27,192 | $850 |
| Return visit (30+ min) | 84 | $15,507 | $89 |
| Return visit (30+ min) | 85 | $12,913 | $91 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 27 | $6,880 | $255 |
| Long return visit (40+ min) | 22 | $5,306 | $126 |
| Imaging of lymph nodes during surgery | 32 | $5,221 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $5,105 | $65 |
| Long return visit (40+ min) | 31 | $4,960 | $121 |
| New patient visit (45+ min) | 36 | $4,582 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $4,256 | $185 |
| Short return visit (20+ min) | 53 | $2,930 | $46 |
| New patient visit (45+ min) | 21 | $2,528 | $120 |
| New patient visit (60+ min) | 16 | $2,508 | $157 |
| New patient visit (60+ min) | 14 | $2,372 | $169 |
| Short return visit (20+ min) | 37 | $2,353 | $50 |
| Short return visit | 12 | $548 | $34 |
| Short return visit | 14 | $439 | $31 |
2020: 11 services
| Return visit (30+ min) | 110 | $20,120 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 47 | $15,952 | $66 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 17 | $14,111 | $830 |
| Return visit (30+ min) | 81 | $12,561 | $69 |
| New patient visit (60+ min) | 50 | $7,270 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,936 | $185 |
| New patient visit (60+ min) | 36 | $5,393 | $150 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 15 | $3,242 | $216 |
| Imaging of lymph nodes during surgery | 17 | $2,910 | $171 |
| Short return visit (20+ min) | 53 | $2,683 | $43 |
| Short return visit (20+ min) | 33 | $1,647 | $43 |
2019: 11 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 19 | $15,079 | $794 |
| Return visit (30+ min) | 89 | $13,194 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $10,892 | $66 |
| Return visit (30+ min) | 78 | $10,279 | $68 |
| New patient visit (60+ min) | 51 | $7,455 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,956 | $184 |
| New patient visit (60+ min) | 28 | $4,195 | $150 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 17 | $3,684 | $217 |
| Imaging of lymph nodes during surgery | 20 | $3,466 | $173 |
| Short return visit (20+ min) | 36 | $1,476 | $39 |
| Short return visit (20+ min) | 31 | $1,468 | $40 |
2018: 12 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 22 | $17,447 | $793 |
| Return visit (30+ min) | 96 | $14,659 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $11,374 | $65 |
| Return visit (30+ min) | 69 | $9,490 | $68 |
| New patient visit (60+ min) | 57 | $7,953 | $140 |
| New patient visit (60+ min) | 43 | $6,042 | $141 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $4,548 | $182 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 14 | $3,194 | $228 |
| Short return visit (20+ min) | 41 | $2,042 | $39 |
| Short return visit (20+ min) | 39 | $1,943 | $40 |
| Long return visit (40+ min) | 11 | $1,097 | $100 |
| Other procedure on lymphatic system | 14 | $711 | $51 |
2017: 9 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 19 | $14,271 | $751 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $9,134 | $65 |
| Return visit (30+ min) | 51 | $8,195 | $67 |
| Return visit (30+ min) | 46 | $7,812 | $65 |
| New patient visit (60+ min) | 45 | $6,652 | $148 |
| New patient visit (60+ min) | 35 | $5,058 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,976 | $178 |
| Short return visit (20+ min) | 47 | $2,859 | $43 |
| Short return visit (20+ min) | 41 | $2,236 | $44 |
2016: 8 services
| Return visit (30+ min) | 54 | $7,004 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $6,687 | $64 |
| Return visit (30+ min) | 49 | $6,444 | $66 |
| New patient visit (60+ min) | 35 | $5,081 | $145 |
| New patient visit (60+ min) | 31 | $4,634 | $149 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,983 | $180 |
| Short return visit (20+ min) | 29 | $1,504 | $42 |
| Short return visit (20+ min) | 24 | $1,230 | $42 |
2015: 8 services
| Return visit (30+ min) | 82 | $12,802 | $69 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 19 | $12,002 | $632 |
| Removal of ovaries and/or tubes using an endoscope | 14 | $10,609 | $758 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $7,709 | $65 |
| New patient visit (60+ min) | 49 | $7,306 | $149 |
| New patient visit (60+ min) | 18 | $3,412 | $190 |
| Return visit (30+ min) | 27 | $3,057 | $83 |
| Long return visit (40+ min) | 20 | $1,989 | $99 |
2014: 8 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 15 | $13,993 | $933 |
| Return visit (30+ min) | 42 | $6,223 | $70 |
| New patient visit (60+ min) | 29 | $4,338 | $150 |
| New patient visit (60+ min) | 23 | $4,333 | $188 |
| Long return visit (40+ min) | 20 | $2,467 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,434 | $64 |
| Return visit (30+ min) | 17 | $2,302 | $100 |
| New patient visit (45+ min) | 11 | $1,272 | $116 |
2013: 6 services
| New patient visit (60+ min) | 27 | $4,392 | $163 |
| Short return visit (20+ min) | 48 | $3,068 | $57 |
| Return visit (30+ min) | 30 | $2,813 | $83 |
| New patient visit (45+ min) | 19 | $2,417 | $127 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 21 | $1,333 | $61 |
| Long return visit (40+ min) | 11 | $1,272 | $116 |
Medicaid work
$8,532 in 2024
Medicaid paid $8,532 for 138 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 106 | $5,982 |
| Long return visit (40+ min) | 14 | $1,416 |
| Short return visit (20+ min) | 18 | $1,134 |
| 2024 | 138 | 3 | 17 | $8,532 |
| 2023 | 343 | 2 | 25 | $11,854 |
| 2022 | 241 | 2 | 24 | $9,720 |
| 2021 | 126 | 2 | 18 | $5,174 |
| 2020 | 226 | 1 | 31 | $8,303 |
| 2019 | 245 | 2 | 35 | $7,343 |
| 2018 | 271 | 2 | 29 | $7,961 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 248 | $9,652 |
| Short return visit (20+ min) | 95 | $2,202 |
2022
| Return visit (30+ min) | 177 | $8,009 |
| Short return visit (20+ min) | 64 | $1,711 |
2021
| Return visit (30+ min) | 111 | $4,892 |
| Short return visit (20+ min) | 15 | $282 |
2020
| Return visit (30+ min) | 226 | $8,303 |
2019
| Return visit (30+ min) | 228 | $6,903 |
| Short return visit (20+ min) | 17 | $441 |
2018
| Return visit (30+ min) | 254 | $7,585 |
| Short return visit (20+ min) | 17 | $376 |
Drugs they prescribed that Part D paid
$745,102
Pharmacies billed $745,102 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (12 of 424) in 2024. At or below the middle of the specialty; the typical gynecological oncology clinician is at 13%.
345 generic and 79 brand-name prescriptions · $745,102 in drug cost · 18 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lynparza | 33 | $354,487 | $10,742 |
| Orserdu | 11 | $225,836 | $20,531 |
| Prochlorperazine Maleate | 44 | $399 | $9 |
| Ondansetron | 61 | $219 | $4 |
| Lorazepam | 25 | $116 | $5 |
See all 9 drugs
| Lynparza | 33 | $354,487 | $10,742 |
| Orserdu | 11 | $225,836 | $20,531 |
| Prochlorperazine Maleate | 44 | $399 | $9 |
| Ondansetron | 61 | $219 | $4 |
| Lorazepam | 25 | $116 | $5 |
| Pantoprazole | 24 | $104 | $4 |
| Metoclopramide | 23 | $97 | $4 |
| Lisinopril | 13 | $78 | $6 |
| Amlodipine Besylate | 13 | $29 | $2 |
Year by year
| 2024 | 424 | 95 | 3% (12) | 19% | $745,102 |
| 2023 | 281 | 81 | 6% (18) | None | $367,703 |
| 2022 | 287 | 69 | 4% (12) | 19% | $378,971 |
| 2021 | 372 | 89 | 10% (36) | 17% | $681,754 |
| 2020 | 501 | 98 | 9% (47) | 17% | $442,769 |
| 2019 | 480 | 118 | 6% (28) | 21% | $663,646 |
| 2018 | 586 | 123 | 8% (45) | None | $540,609 |
| 2017 | 306 | 77 | 5% (15) | None | $143,145 |
| 2016 | 233 | 61 | 8% (18) | 14% | $101,439 |
| 2015 | 220 | 60 | 7% (16) | None | $110,765 |
| 2014 | 108 | 43 | 19% (21) | None | $5,590 |
| 2013 | 137 | 45 | 10% (13) | 18% | $16,614 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Lynparza | 17 | $210,342 | $12,373 |
| Prochlorperazine Maleate | 35 | $354 | $10 |
| Ondansetron | 38 | $242 | $6 |
| Oxycodone | 15 | $126 | $8 |
| Lorazepam | 18 | $96 | $5 |
| Metoclopramide | 21 | $93 | $4 |
2022: 8 drugs
| Eliquis | 13 | $7,473 | $575 |
| Premarin | 13 | $3,882 | $299 |
| Medroxyprogesterone Acetate | 13 | $828 | $64 |
| Ondansetron | 39 | $428 | $11 |
| Prochlorperazine Maleate | 29 | $346 | $12 |
| Tamoxifen Citrate | 11 | $230 | $21 |
| Estradiol | 11 | $142 | $13 |
| Metoclopramide | 19 | $68 | $4 |
2021: 8 drugs
| Rubraca | 18 | $242,058 | $13,448 |
| Megestrol Acetate | 17 | $888 | $52 |
| Prochlorperazine Maleate | 21 | $299 | $14 |
| Ondansetron | 31 | $220 | $7 |
| Tamoxifen Citrate | 15 | $217 | $14 |
| Oxycodone | 23 | $198 | $9 |
| Metoclopramide | 19 | $97 | $5 |
| Estradiol | 16 | $81 | $5 |
2020: 13 drugs
| Rubraca | 21 | $276,476 | $13,166 |
| Enoxaparin | 12 | $2,142 | $179 |
| Letrozole | 17 | $721 | $42 |
| Prochlorperazine Maleate | 42 | $696 | $17 |
| Megestrol Acetate | 11 | $688 | $63 |
| Oxycodone | 17 | $333 | $20 |
| Ondansetron | 34 | $321 | $9 |
| Tamoxifen Citrate | 12 | $242 | $20 |
| Lorazepam | 30 | $110 | $4 |
| Metoclopramide | 23 | $77 | $3 |
| Hydrocodone-Acetaminophen | 11 | $72 | $7 |
| Amlodipine Besylate | 13 | $58 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $47 | $4 |
2019: 17 drugs
| Rubraca | 22 | $267,099 | $12,141 |
| Lynparza | 14 | $159,080 | $11,363 |
| Zejula | 11 | $143,612 | $13,056 |
| Eliquis | 13 | $6,195 | $477 |
| Estradiol | 13 | $1,554 | $120 |
| Tamoxifen Citrate | 11 | $494 | $45 |
| Megestrol Acetate | 18 | $487 | $27 |
| Letrozole | 16 | $413 | $26 |
| Gabapentin | 16 | $366 | $23 |
| Prochlorperazine Maleate | 32 | $325 | $10 |
| Lidocaine-Prilocaine | 11 | $194 | $18 |
| Ondansetron Odt | 18 | $141 | $8 |
| Lorazepam | 29 | $138 | $5 |
| Metoclopramide | 26 | $119 | $5 |
| Oxycodone | 14 | $102 | $7 |
| Ondansetron | 23 | $101 | $4 |
| Amlodipine Besylate | 15 | $23 | $2 |
2018: 15 drugs
| Zejula | 14 | $182,062 | $13,004 |
| Rubraca | 14 | $168,450 | $12,032 |
| Lynparza | 17 | $161,506 | $9,500 |
| Enoxaparin | 20 | $5,255 | $263 |
| Estradiol | 18 | $1,515 | $84 |
| Polyethylene Glycol 3350 | 17 | $478 | $28 |
| Megestrol Acetate | 21 | $415 | $20 |
| Ondansetron | 50 | $305 | $6 |
| Prochlorperazine Maleate | 40 | $255 | $6 |
| Ondansetron Odt | 30 | $247 | $8 |
| Lorazepam | 46 | $193 | $4 |
| Hydrocodone-Acetaminophen | 21 | $179 | $9 |
| Oxycodone | 15 | $141 | $9 |
| Metoclopramide | 25 | $122 | $5 |
| Ibuprofen | 14 | $63 | $5 |
2017: 11 drugs
| Lynparza | 11 | $74,766 | $6,797 |
| Enoxaparin | 15 | $5,307 | $354 |
| Megestrol Acetate | 16 | $444 | $28 |
| Sodium Chloride | 18 | $376 | $21 |
| Ondansetron Odt | 15 | $155 | $10 |
| Prochlorperazine Maleate | 18 | $112 | $6 |
| Ondansetron | 19 | $99 | $5 |
| Metoclopramide | 11 | $66 | $6 |
| Lorazepam | 12 | $56 | $5 |
| Ibu | 11 | $53 | $5 |
| Ibuprofen | 11 | $41 | $4 |
2016: 3 drugs
| Enoxaparin | 13 | $5,246 | $404 |
| Ondansetron | 27 | $241 | $9 |
| Ibuprofen | 18 | $95 | $5 |
2015: 4 drugs
| Lynparza | 13 | $73,404 | $5,646 |
| Ondansetron | 12 | $164 | $14 |
| Ibuprofen | 20 | $116 | $6 |
| Lorazepam | 14 | $49 | $3 |
2014: 2 drugs
| Hydrocodone-Acetaminophen | 17 | $186 | $11 |
| Ibuprofen | 13 | $69 | $5 |
2013: 1 drug
| Estradiol | 15 | $288 | $19 |
Money from drug and device companies
$21,894 in 2025
| 2025 | 4 | 29 | $20,060 | $21,894 |
| 2024 | 6 | 15 | $4,175 | $7,069 |
| 2023 | 3 | 13 | $10,102 | $11,731 |
| 2022 | 4 | 22 | $26,650 | $29,135 |
| 2021 | 3 | 21 | $28,733 | $29,311 |
| 2020 | 3 | 19 | $21,975 | $22,576 |
| 2019 | 5 | 43 | $39,308 | $46,610 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Lynparza | $8,661 | 8 payments
|
| Merck Sharp & Dohme | Keytruda | $6,015 | 6 payments
|
| Abbvie | Elahere | $3,807 | 9 payments
|
| Corcept Therapeutics | None | $3,411 | 6 payments
|
See all 29 published payments
| Corcept Therapeutics | Paid to speak or teach · 2025-12-23 | None | $3,200 |
| Corcept Therapeutics | Travel · 2025-12-23 | None | $26 |
| Corcept Therapeutics | Meals · 2025-12-23 | None | $8 |
| Corcept Therapeutics | Travel · 2025-12-23 | None | $48 |
| Corcept Therapeutics | Meals · 2025-12-13 | None | $50 |
| Corcept Therapeutics | Meals · 2025-12-13 | None | $80 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Lynparza | $121 |
| Merck Sharp & Dohme | Travel · 2025-10-17 | Keytruda | $75 |
| Merck Sharp & Dohme | Paid to speak or teach · 2025-10-17 | Keytruda | $5,760 |
| Abbvie | Meals · 2025-10-07 | Elahere | $39 |
| Abbvie | Travel · 2025-10-07 | Elahere | $50 |
| Abbvie | Consulting · 2025-10-07 | Elahere | $2,900 |
| Abbvie | Travel · 2025-10-07 | Elahere | $24 |
| Merck Sharp & Dohme | Meals · 2025-09-28 | Keytruda | $110 |
| Abbvie | Meals · 2025-09-12 | Elahere | $24 |
| Abbvie | Travel · 2025-09-12 | Elahere | $321 |
| Abbvie | Meals · 2025-09-12 | Elahere | $66 |
| Abbvie | Meals · 2025-09-11 | Elahere | $77 |
| Abbvie | Travel · 2025-09-11 | Elahere | $307 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-27 | None | $12 |
| Merck Sharp & Dohme | Meals · 2025-08-22 | Keytruda | $18 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-24 | Lynparza | $3,280 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-07-24 | Lynparza | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-17 | Lynparza | $125 |
| Merck Sharp & Dohme | Meals · 2025-05-16 | Keytruda | $20 |
| Merck Sharp & Dohme | Meals · 2025-03-28 | Keytruda | $32 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-20 | Lynparza | $4,920 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-03-14 | Lynparza | $65 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Lynparza | $115 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $7,069
| AstraZeneca Pharmaceuticals LP | Lynparza | $2,916 | 3 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $2,540 | 2 payments
|
| EMD Serono Research & Development Institute | None | $1,425 | 1 payment
|
| Merck Sharp & Dohme | Lynparza | $95 | 4 payments
|
| GlaxoSmithKline | Zejula | $65 | 1 payment
|
| Ethicon US | Surgiflo Hemostatic Matrix | $28 | 1 payment
|
2023: $11,731
| AstraZeneca Pharmaceuticals LP | Lynparza | $6,943 | 3 payments
|
| GlaxoSmithKline | Jemperli | $3,237 | 8 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $1,552 | 2 payments
|
2022: $29,135
| GlaxoSmithKline | Zejula | $27,801 | 18 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $1,050 | 1 payment
|
| Conmed | Airseal | $269 | 2 payments
|
| Pfizer | None | $15 | 1 payment
|
2021: $29,311
| GlaxoSmithKline | Zejula | $17,283 | 12 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $8,828 | 7 payments
|
| Clovis Oncology | Rubraca | $3,200 | 2 payments
|
2020: $22,576
| AstraZeneca Pharmaceuticals LP | Lynparza | $7,798 | 7 payments
|
| GlaxoSmithKline | Zejula | $7,671 | 4 payments
|
| Clovis Oncology | Rubraca | $7,107 | 8 payments
|
2019: $46,610
| Clovis Oncology | Rubraca | $40,962 | 36 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $3,383 | 2 payments
|
| Tesaro | Zejula | $1,925 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $211 | 2 payments
|
| Merck Sharp & Dohme | Lynparza | $130 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca UK Limited · A Phase 2a Randomized Double Blind Placebo-Controlled Study To Evaluate the Efficacy and Safety of Medi3506 in Subjects With Diabetic Kidney Disease · 2022 | Their institution | $9,188 |
| AstraZeneca Pharmaceuticals LP · A Phase 2a Randomized Double Blind Placebo-Controlled Study To Evaluate the Efficacy and Safety of Medi3506 in Subjects With Diabetic Kidney Disease · 2022 | Their institution | $3,653 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1851308860
- Licence
- CA A87777California A87777: Current · expires 2028-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A877770
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207V00000X (207V00000X); Federal specialty code 207VH0002X (207VH0002X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-02
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2589 Samaritan Dr, San Jose, CA, 95124